BridgeBio Pharma Inc

Common Name

BridgeBio Pharma

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

725

Ticker

BBIO

Exchange

NASDAQ/NGS

Website

bridgebio.com

Description

BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purp... Show more

Financial Statements of BridgeBio Pharma

Below are the financial statements of BridgeBio Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in thousands of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	681,101^a	375,935^a
Investments in equity securities	0^a	58,949^a
Accounts receivable	4,722^a	1,751^a
Restricted cash	126^a	16,653^a
Prepaid expenses and other current assets	34,743^a	24,305^a
Total current assets	720,692^a	477,593^a
Assets	—	—
Investment in nonconsolidated entities	143,747^a	0^a
Property and equipment, net	7,011^a	11,816^a
Operating lease right-of-use assets	5,767^a	8,027^a
Intangible assets, net	23,926^a	26,319^a
Other assets	18,195^a	22,625^a
Total assets	919,338^a	546,380^a
Current liabilities	—	—
Accounts payable	9,618^a	10,655^a
Accrued compensation and benefits	58,329^a	57,370^a
Accrued research and development liabilities	34,272^a	29,765^a
Operating lease liabilities, current portion	4,506^a	4,128^a
Deferred revenue, current portion	14,604^a	6,096^a
Accrued professional and other accrued liabilities	33,071^a	35,830^a
Total current liabilities	154,400^a	143,844^a
Liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit	—	—
2029 notes, net	738,872^a	736,905^a
2027 notes, net	545,173^a	543,379^a
Term loan, net	437,337^a	446,445^a
Deferred royalty obligation, net	479,091^a	0^a
Operating lease liabilities, net of current portion	4,696^a	8,981^a
Deferred revenue, net of current portion	17,095^a	3,727^a
Other long-term liabilities	286^a	5,634^a
Total liabilities	2,376,950^a	1,888,915^a
Redeemable convertible noncontrolling interests	142^a	478^a
Stockholders’ deficit	—	—
Undesignated preferred stock	0^a	0^a
Common stock	196^a	181^a
Treasury stock, at cost	-275,000^a	-275,000^a
Additional paid-in capital	1,903,155^a	1,481,032^a
Accumulated other comprehensive income	8^a	31^a
Accumulated deficit	-3,096,263^a	-2,560,501^a
Total BridgeBio stockholders’ deficit	-1,467,904^a	-1,354,257^a
Noncontrolling interests	10,150^a	11,244^a
Total stockholders’ deficit	-1,457,754^a	-1,343,013^a
Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit	919,338^a	546,380^a

Verified Sources Behind BridgeBio Pharma’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore BridgeBio Pharma’s data sources below and access millions more through our Disclosure Search.

a. BridgeBio Pharma's 10-K 2024

Trace every data point back to BridgeBio Pharma’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

BridgeBio Pharma Inc

Financial Statements of BridgeBio Pharma

Verified Sources Behind BridgeBio Pharma’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

TG Therapeutics Inc

Vericel Corp

Blueprint Medicines Corp

ADMA Biologics Inc

Ultragenyx Pharmaceutical Inc

Axsome Therapeutics Inc